Mission Improbable

Herper, Matthew; Barron, Rachel
October 2005
Forbes Asia;10/31/2005, Vol. 1 Issue 6, p114
The article focuses on the effectiveness of the AP23573 cancer drug from Ariad Pharmaceuticals in treating cancer. The drug has been effective in completely treating sarcoma. The company's shares have increased 20% in 2004 following the introduction of the drug. The drug works by tripping a cellular switch that was discovered by scientists studying unrelated drug Rapamune.


Related Articles

  • Positive Phase III Results May Mean Big Payday for Ariad. Shaffer, Catherine // BioWorld Today;1/19/2011, Vol. 22 Issue 12, p1 

    The article reports that the SUCCEED Phase III trial of ridaforolimus from Ariad Pharmaceuticals Inc. for the treatment of metastatic soft-tissue or bone sarcoma, has demonstrated the potential effectiveness of the drug. The trial has revealed a 28 percent reduction in the risk of progression...

  • Ariad's Ridaforolimus Follows Tarceva, Alimta in PFS Test. Boggs, Jennifer // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p3 

    The article reports on the approval of the mTOR inhibitor ridaforolimus for sarcoma maintenance therapy from Ariad Pharmaceuticals Inc. It notes that the drug has been successful in a special protocol assessment-conducted Phase III trial. According in a study designated as SUCCEED, the drug...

  • Ariad Hoping To 'Succeed' In Phase III Study Of Deforolimus. Boggs, Jennifer // BioWorld Today;9/25/2007, Vol. 18 Issue 186, p1 

    The article reports on a Phase III trial launched by Ariad Pharmaceuticals Inc. and Merck & Co. Inc. to test the effect of deforolimus on progression-free survival in patients with metastatic soft-tissue and bone sarcomas. According to Harvey Berger, chairman and CEO of Ariad, the Sarcoma...

  • Merck Considers Paying Big Bucks For Ariad Drug.  // njbiz;7/16/2007, Vol. 20 Issue 30, p6 

    The article reports that Merck & Co. may pay as much as $1.1 billion to Ariad Pharmaceuticals Inc. for a late-stage treatment for cancer. The drug will target cancers of the connective tissues called metastatic sarcomas. The company will also receive as much as $652 for meeting certain...

  • Innovations in Oncology Research. Gresham, Aimie // Equities;Apr2008, Vol. 57 Issue 3, p52 

    The article offers examines the investment opportunity offered by the potential vast market for cancer treatment. Partnerships have been sought by big pharmaceutical firms with small biotechnology firms and innovators, such as Ariad and Chemokine Therapeutics. Ziad Bakari of the investment firm...

  • Cancer News Round-up.  // PharmaWatch: Cancer;Jun2010, Vol. 9 Issue 6, p2 

    The article offers news briefs related to drug development for cancer. Bavarian Nordic A/S has received Fast Track status from the U.S. Food and Drug Administration (FDA) for its Prostvac drug for prostate cancer. The European Commission has approved Tarceva as a monotherapy maintenance...

  • Earnings Roundup.  // BioWorld Today;5/8/2013, Vol. 24 Issue 88, p2 

    This article reports on Ariad Pharmaceuticals Inc.'s total net sales of 6.4 million U.S. dollars for the quarter ending March 31, 2013 from cancer drug Iclusig, which is used in adults with chronic myelogenous leukemia of Philadelphia chromosome-positive accute lymphoblastic leukemia.

  • Breast Cancer Update.  // PharmaWatch: Cancer;Jun2005, Vol. 4 Issue 6, p6 

    The article offers news briefs on breast cancer medical drug development. Avastin, a drug developed by Genentech Inc. and Roche, has a potential towards improved progression-free survival in patients with breast cancer when it is integrated with chemotherapy. Ariad Pharmaceuticals Inc. has begun...

  • ARIAD to Webcast Conference Call on 1st qtr 2011 Financial Results.  // Biomedical Market Newsletter;5/28/2011, p500 

    The article focuses on Ariad Pharmaceuticals Inc. which will be hosting a conference call on May 5, 2011 in Cambridge, Massachusetts. It notes that the discussions on the said conference will be the financial results of the company for the first quarter of 2011, business planning, and other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics